Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4
3(100.0%)
3Total
Phase 4(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04640818Unknown

Safety and Efficacy of Cladribine Therapy After Anti CD20 Therapy

Role: lead

NCT02082002Completed

Multidimensional Assessment of Fatigue in Multiple Sclerosis- Observational Study - Ticino

Role: lead

NCT01411514Phase 4Terminated

Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis

Role: lead

NCT01144052Phase 4Completed

Natalizumab De-escalation With Interferon Beta-1b

Role: lead

NCT01701856Phase 4Terminated

Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis

Role: lead

All 5 trials loaded